Dr. Anjani Jha is the President and CEO of MAA Laboratories and has a deep understanding of the pharmaceutical business. He has extensive experience in drug and technology development at Pii, MIT, GSK, and Rhodes and has worked with small molecules in various therapeutic classes and dosage forms from the preclinical stage to commercialization. Dr. Jha has launched several products in the areas of anti-cancer, anti-inflammatory, hypertension, respiratory, pain management, and ADHD using nano drug delivery and continuous manufacturing approaches. At the Novartis-MIT Center, he was involved in the development and integration of the first end-to-end continuous manufacturing process for pharmaceuticals. In addition to industry experience of increasing responsibility, Dr. Jha formed and led teams through student leadership activities. He has completed his Post-doctoral work from the Massachusetts Institute of Technology (MIT) and received a PhD from Pennsylvania State University. Dr. Jha is also an alumnus of Indian Institute of Technology Kharagpur.
Mr. Pieter de Ridder is the Chief Business Officer of MAA Laboratories. Mr. de Ridder has 20+ years of global leadership experience in Business Development and Commercial Operations of generics and biotech companies, and in management consulting roles. He has a proven track record of driving growth through rigorous planning and execution of well thought-out strategies in established and startup companies. Most recently, Mr. de Ridder was President of Glycan Therapeutics, an emerging biotech company, specialized in glycobiology based on its proprietary chemoenzymatic oligosaccharide synthesis platform. Previously he was Vice President Sales and Marketing and Chief Commercial Officer for Synthon, a global specialty pharmaceutical company specialized in the development, manufacturing and marketing of generics and branded biopharmaceutical products. He has extensive experience in commercial strategy, sales, business development, and licensing of pharmaceutical products in North America and Europe. Mr. de Ridder holds an MBA from Duke University in Durham, NC.
Dr. Tage Honoré is currently serving as the President of Aestus Partners. He is also serving as the founding member of the scientific advisory board at Forge Life Science and chairman of the board Dep-Xplora Aps and previously served as Vice President of Discovery Research. Dr. Honore also served as the Senior Executive Vice President at Novartis. Before Novartis, he served as the Vice President of Discovery Research at Novo Nordisk. As a pharma executive, Dr. Honore championed development of ideas to early clinical studies in cancer immunotherapy, alzheimer’s disease, anxiety, chronic pain, depression, epilepsy, female hormone replacement therapy, learning disorders, osteoporosis, Parkinson’s disease, stroke and schizophrenia. Dr. Honore contributed to more than 40 new molecular entities entering clinical development of which three were launched, and he managed budgets for a total of approximately $1B. Dr. Honore developed organizational models to obtain record pipeline productivity in several companies and entrepreneurial value creation by integration of research, clinical, marketing and financial stakeholders. He published more than 100 scientific journal articles and is an inventor on 23 patents. His Doctoral degrees in Medicinal Chemistry and Neurobiology and business training are from Harvard Business School and European Management Centre.
Behnam Pourdeyhimi is the Klopman Distinguished Professor of Textile Materials and Associate Dean for Industry Research and Extension at North Carolina State University (NCSU). He also serves as the Director of the Nonwovens Cooperative Research Center at the College of Textiles at NCSU. Dr. Pourdeyhimi received his Ph. D. from Leeds University. This was followed by positions as a research scientist at NCSU and then at Cornell University. His distinguished academic career has taken him through the University of Maryland and Ga. Tech. before returning to NC State. Dr. Pourdeyhimi has taught textile and fiber science, technology and engineering as well as microscopy and image analysis applications to textiles, nonwovens and materials problems both at undergraduate and graduate levels. His research experience covers such areas as image and structural analysis of nonwoven fibrous webs, textile applications in sports, bioengineering and materials, instrumentation and test method development, among others. His contributions to fiber/textile science, engineering and technology and his contributions to the profession have been well recognized by several awards. He has published several books and monographs, over 150 refereed journal articles, and given over 150 conference presentations. He is the recipient of The Fiber Society Young Distinguished Achievement Award and Fellowship of the Textile Institute, and he also served as the President of the Fiber Society. His students have won several awards, including the Fiber Society Best Paper award and the INTC Best Paper Award. Dr. Pourdeyhimi's research interests are in the area of nonwovens, materials, biomaterials, modeling performance, special textile structures, and image analysis. His expertise is recognized by major corporations and leading research organizations around the world. He has served as a consultant to more than 30 organizations and major Corporations.
Mr. Buzogany is an accomplished board director and C-level executive (CEO/COO/CLO) over the past 30 years with both public and private companies ranging in size from very early stage to multinationals. He has built a track record of high achievement and solid leadership as an operations, legal, and corporate governance executive at each of the biopharmaceutical, life sciences, and contract research organizations that he has served. Recent past companies and positions include: Board Chairman of PillGuard Medication Delivery Systems, a medical device company; President & CEO of Jenken Biosciences, Inc. a startup drug development company; and COO and General Counsel of Icoria, Inc., a publicly traded life sciences company. Mr. Buzogany is currently focused on board-level service and executive mentoring.
Jarrett Disbrow is currently serving as the Chief Operating Officer at Aytu BioScience. Mr. Disbrow previously served as President & CEO of Vyrix Pharmaceuticals since November 2013 until the merger to form Aytu BioScience in April 2015. He has over eighteen years of experience in the pharmaceutical industry with “Big Pharma” and specialty pharmaceutical companies and was the Founder, President and Chief Executive Officer of Arbor Pharmaceuticals – a specialty pharmaceutical company focused initially on pediatrics. As the sole founder of Arbor he was responsible for all aspects of the company’s start-up and growth phases including fundraising, business and product development, commercial strategy, product marketing and partnering. He was also responsible for negotiating the acquisition of the company to a private investor group in 2010 and remained with the company, post-acquisition, as Vice President of Commercial Development. In less than five years Arbor grew from a company with no product revenues to net sales in excess of $127 million. Prior to founding Arbor Pharmaceuticals, he was head of marketing for Accentia Biopharmaceuticals, Inc. Mr. Disbrow began his career with GlaxoWellcome, Inc. (now GlaxoSmithKline plc) where he held positions of increasing responsibility in sales and marketing. He received a BS in Business Management from North Carolina State University in Raleigh, NC.